COVID-19
- USP Statement to the 73rd World Health Assembly Agenda Item 3: Address by WHO Director-General, devoted to the COVID-19 pandemic response
- USP Statement to the 74th World Health Assembly Agenda Item 16.1: COVID-19 Respons
- USP Statement to the 74th World Health Assembly Agenda Item 13.5: Antimicrobial resistance
- USP Statement to the 74th World Health Assembly Agenda Item 13.6: Substandard and falsified medical products
- September 2020 – USP Statement to the 73rd Session of WHO Regional Committee for South-East Asia on access to medicines
- USP Statement on the World Health Organization's (WHO) Publication: Delivering Quality-Assured Medical Products for All 2019-2023 – WHO's Five-Year Plan to Help Build Effective and Efficient Regulatory Systems
- USP Statement to the 72nd World Health Assembly Agenda Item 12.2: Member State mechanism on substandard and falsified medical products
- USP Statement to the 72nd World Health Assembly Agenda Item 11.8: Follow-up to the high-level meetings of the United Nations General Assembly on health related issues
- USP Statement to the 72nd World Health Assembly Agenda Item 11.7: Access to medicines and vaccines
USP joined the 144th Session of WHO's Executive Board Meeting to lend our voice highlighting medicines quality across global health agendas. Read USP's Statements on:
- WHO's Roadmap on Access to Medicines and Vaccines
- Antimicrobial Resistance action
- Member State mechanism on substandard and falsified medical products
- May 2018 - Statements to the 71st World Health Assembly on prevention and control of non-communicable diseases and ending tuberculosis
- September 2018 - Statement to the 71st Session of WHO Regional Committee for South-East Asia on efforts to strengthen the health workforce